Subsequently, immunotherapy has been introduced as a first-line treatment, either as a combination of nivolumab and ipilimumab (an anti-CTLA-4 antibody) for patients at intermediate and poor risk according to the International Metastatic RCC Database Consortium (IMDC) prognostic index or with anti-PD-1/anti-PD-L1 antibodies in combination with antiangiogenic therapy across all IMDC patient groups [2]. The gene discussed is CTLA4; the disease is renal cell carcinoma.